(Q39576903)

13 September 2017

title

Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin (English)

1 reference

13 September 2017

1 reference

Michael Groessl

1

0 references

Paul Dyson

object named as

Paul J Dyson

series ordinal

3

0 references

author name string

Olivier Zava

series ordinal

2

1 reference

13 September 2017

publication date

11 March 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

3

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

591-599

1 reference

Metal-based antitumour drugs in the post genomic era.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Inhibition of transcription by platinum antitumor compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Analytical methodologies for the determination of cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Non platinum metal complexes as anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

A categorization of metal anticancer compounds based on their mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Antitumour metal compounds: more than theme and variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Advances in analytical methodology for bioinorganic speciation analysis: metallomics, metalloproteomics and heteroatom-tagged proteomics and metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Mass spectrometry in bioinorganic analytical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

The emerging role of ICP-MS in proteomic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

A cytotoxic ruthenium tris(bipyridyl) complex that accumulates at plasma membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

The actin cytoskeleton in cancer cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Mitochondria: more than just a powerhouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

DNA-based drug interactions of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Cell biological mechanisms of multidrug resistance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Serum and plasma proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Encapsulation of platinum anticancer drugs by apoferritin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Stability, accumulation and cytotoxicity of an albumin-cisplatin adduct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

Site selectivity of platinum anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MT00101E

21 January 2018

Identifiers

DOI

10.1039/C0MT00101E

1 reference

13 September 2017

1 reference